CIK 0002044725 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Evommune, Inc.
Sign in to watch- Ticker
- EVMN
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 850742575
- Phone
- (650) 223-7745
- Business address
- 1891 PAGE MILL RD, PALO ALTO, CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-30 | Pena Luis C. President & CEO | Grant or award | +1,115 | $7.02 | $8K | 631,573 |
| 2026-07-08 | Carver Kyle Chief Financial Officer | Purchase | +1,000 | $13.26 | $13K | 60,335 |
| 2026-07-07 | KIRSCH ARTHUR S Director | Purchase | +10,000 | $13.30 | $133K | 10,000 |
| 2026-06-22 | Patel Jeegar Pravinkumar Chief Scientific Officer | Option exercise 10b5-1 | +1,488 | $3.84 | $6K | 47,891 |
| 2026-06-22 | Patel Jeegar Pravinkumar Chief Scientific Officer | Sale 10b5-1 | −1,488 | $22.50 | $33K | 46,403 |
| 2026-06-22 | Patel Jeegar Pravinkumar Chief Scientific Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −1,488 | 27,842 | ||
| 2026-06-22 | Drew Janice Suzann Chief of Dev. Operations | Option exercise 10b5-1 | +3,839 | $3.84 | $15K | 71,633 |
| 2026-06-22 | Drew Janice Suzann Chief of Dev. Operations | Option exercise 10b5-1 | +16,161 | $2.99 | $48K | 87,794 |
| 2026-06-22 | Drew Janice Suzann Chief of Dev. Operations | Sale 10b5-1 | −20,000 | $22.63 | $453K | 67,794 |
| 2026-06-22 | Drew Janice Suzann Chief of Dev. Operations | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −3,839 | 53,795 | ||
| 2026-06-22 | Drew Janice Suzann Chief of Dev. Operations | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −16,161 | 39,321 | ||
| 2026-06-22 | Pena Luis C. President & CEO | Sale 10b5-1 | −7,438 | $22.71 | $169K | 630,458 |
| 2026-06-02 | Cohen David E Director | Sale 10b5-1 | −5,456 | $20.21 | $110K | 18,209 |
| 2026-06-02 | Cohen David E Director | Sale 10b5-1 | −600 | $21.38 | $13K | 17,609 |
| 2026-06-02 | Cohen David E Director | Grant or award · Stock Option (Right to buy) 10b5-1 | +15,673 | 15,673 | ||
| 2026-06-02 | KIRSCH ARTHUR S Director | Grant or award · Stock Option (Right to buy) | +15,673 | 15,673 | ||
| 2026-06-02 | MCGRAW BENJAMIN F III Director | Grant or award · Stock Option (Right to buy) | +15,673 | 15,673 | ||
| 2026-06-01 | Patel Jeegar Pravinkumar Chief Scientific Officer | Option exercise 10b5-1 | +13,512 | $3.84 | $52K | 63,090 |
| 2026-06-01 | Patel Jeegar Pravinkumar Chief Scientific Officer | Sale 10b5-1 | −16,687 | $22.74 | $379K | 46,403 |
| 2026-06-01 | Patel Jeegar Pravinkumar Chief Scientific Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −13,512 | 29,330 |
Page 1 of 6 · 109 trades